<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03983655</url>
  </required_header>
  <id_info>
    <org_study_id>GER-2962-19-20-1</org_study_id>
    <nct_id>NCT03983655</nct_id>
  </id_info>
  <brief_title>Effect of High Frequency/Low Intensity Transcranial Magnetic Stimulation in Cognitive Traits of an Elderly Population of Subjects With Mild Cognitive Impairment and Mild Dementia.</brief_title>
  <official_title>Effect of High Frequency/Low Intensity Transcranial Magnetic Stimulation in Cognitive Traits of an Elderly Population of Subjects With Mild Cognitive Impairment and Mild Dementia: A Randomized, Double Blind, Parallel Group, Sham Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Actipulse Neuroscience</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are no pharmacological interventions that delay or prevent the transition of mild
      cognitive impairment to dementia. Several studies have shown that transcranial magnetic
      stimulation (TMS) could be useful in increasing cognitive traits in dementia.

      As TMS is performed in a clinical setting, transportation, mobility and high costs of
      treatment, limit the number of TMS sessions dementia patients can receive. Most of the trials
      do not apply more than 20 TMS sessions

      Here, a randomized, sham controlled, paralallel group, clinical trial will be performed in
      order to asess the efficacy at improving cognitive traits of a novel TMS device that uses
      high frequency and low intensity pulses. As the device is portable and can be used from home
      without clinical supervision, the stimulation will be applied two times per day for a period
      of 6 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 17, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline ADAS-COG at 6 monts</measure>
    <time_frame>6 months</time_frame>
    <description>Alzheimer´s Disease Assessment Scale-Cognitive</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of total Katz Index of Independence in Activities of Daily Living at 3 months</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of total Katz Index of Independence in Activities of Daily Living at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of total Lawton Instrumental Activities of Daily Living Scale at 3 months</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of total Lawton Instrumental Activities of Daily Living Scale at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of total Geriatric Depression Scale at 3 months</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of total Geriatric Depression Scale at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of total Montreal Cognitive Assessment at 3 months</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of total Montreal Cognitive Assessment at 6 monts</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of total Frontal Asessment Battery at 3 monts</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Frontal Asessment Battery at 6 monts</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Mild Dementia</condition>
  <arm_group>
    <arm_group_label>Real High Frequency Low Intensity TMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two sessions of transcranial magnetic stimulation each day for 6 monts. The coil of the device emits a pulsed magnetic field at an aproximate frequency of 125 hz and an intensity of 10 gauss.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham High Frequency Low Intensity TMS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Two sessions of transcranial magnetic stimulation each day for 6 monts. The coil of the device does not emit a magnetic field.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High Frequency Low Intensity TMS</intervention_name>
    <description>125 hz, 10 gauss, 2 times daily for 6 monts</description>
    <arm_group_label>Real High Frequency Low Intensity TMS</arm_group_label>
    <arm_group_label>Sham High Frequency Low Intensity TMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        IInclusion Criteria:

        ( - ) CDR less or equal to 1 ( - ) Mild cognitive impairment by Petersen criteria ( - )
        Conserved or corrected sight ( - ) Enrolled at INCMNSZ for medical care ( - ) Be able to
        read and write ( - ) Willing and able to provide written informed consent

        Exclusion Criteria:

        ( - ) Other neurodegenerative disorder different than mild cognitive impairment or mild
        dementia ( - ) Metabolic disease without medical care ( - ) Epilepsy ( - ) Deep brain
        stimulator ( - ) Metalic prosthethics in the skulls ( - ) Major depressive disorder ( - )
        Previous utilization of other neuromodulation technique ( - ) Signs or symptoms of
        increased intracraneal pressure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alberto Mimenza, MD</last_name>
    <phone>54870-900</phone>
    <phone_ext>5711</phone_ext>
    <email>alberto.mimenzaa@incmnsz.mx</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</name>
      <address>
        <city>Mexico City</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Mimenza, MD</last_name>
      <phone>54870-900</phone>
      <phone_ext>5711</phone_ext>
      <email>alberto.mimenzaa@incmnsz.mx</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 21, 2019</study_first_submitted>
  <study_first_submitted_qc>June 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2019</study_first_posted>
  <last_update_submitted>June 11, 2019</last_update_submitted>
  <last_update_submitted_qc>June 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</investigator_affiliation>
    <investigator_full_name>Alberto José Mimenza Alvarado</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

